Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review
{{output}}
Background: Patients with stage IA epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) also face recurrence risk, yet whether targeted therapy should be performed remains controversial. We... ...
